Changes in Height, Weight, and Body Mass Index in Children with Craniopharyngioma after Three Years of Growth Hormone Therapy: Analysis of KIGS (Pfizer International Growth Database)
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Extreme degrees of obesity may occur in association with hypothalamic tumors, usually after surgical intervention. This phenomenon has been reported to occur in as many as 25–75% of children undergoing extensive surgical extirpation of craniopharyngiomas (Cranio). Because less is known about the auxology of children with Cranio with milder alterations in growth, we undertook a 3-yr longitudinal analysis, using the KIGS database (Pfizer International Growth Database), to study their growth patterns and evolution of weight. We compared the effect of GH therapy on height, weight, and body mass index (BMI) in 199 prepubertal children with diagnosed Cranio treated by surgery and/or radiotherapy to two other groups of children with other causes of organic GH deficiency (OGHD): one with postsurgical and/or postirradiated OGHD (OGHD + S/I; n = 92) and the other with OGHD not due to Cranio and not having undergone either surgery or irradiation (OGHD − S/I; n = 85). At the start of GH therapy, 1) mean chronological (P < 0.0001) and bone (P = 0.0002) ages were youngest in OGHD − S/I and oldest in OGHD + S/I; 2) the mean height sd score (SDS) was lowest in OGHD − S/I and comparably higher in the other two groups (P < 0.0001); 3) mean weight and BMI SDS were greatest in Cranio and least in OGHD − S/I (both P < 0.0001); and 4) the mean initial GH dose prescribed was highest in OGHD − S/I and comparable in the other two groups (P < 0.0001). After 3 yr of GH therapy, 1) mean bone age remained youngest in OGHD − S/I and oldest in OGHD + S/I (P < 0.0001); 2) mean height SDS was highest in Cranio and comparably lower in the other two groups (P = 0.0159); 3) mean weight and BMI SDS remained greatest in Cranio and least in OGHD − S/I (P < 0.0001 and P = 0.0003, respectively); and 4) the mean GH dose remained highest in the OGHD − S/I group and least in the Cranio group (P = 0.0082). There were statistically significant increases within each group between the start of treatment and after 3 yr of GH therapy in height and weight, but not in BMI SDS. Lastly, after 3 yr of GH treatment, children in the Cranio group continued to have disproportionately heavier weight and higher BMI (with the greatest values in those with lower stimulated peak GH concentrations) compared with members of the other two groups, with no salutary effect of GH treatment on weight SDS and a mild improvement in BMI SDS. After S/I treatment, children with Cranio are disproportionately prone to varying degrees of weight gain compared with children with other forms of OGHD. In the present cohort of prepubertal children with Cranio, GH therapy induced excellent linear growth, but failed to have an ameliorative effect on weight gain and had only a slight beneficial effect on BMI gain. Because affected children may have resultant significant long-term medical morbidity and diminished quality of life, it is critical that the mechanism of this phenomenon be determined to devise helpful preventive or therapeutic interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Features of the metabolic syndrome after childhood craniopharyngioma
Srinivasan, S., Ogle, G. D., Garnett, S. P., Briody, J. N., Lee, J. W., & Cowell, C. T. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030442 · Cited by 211 · cited 1×
“affected with hypothalamic obesity were excluded (20).”
THE GROWTH WITHOUT GROWTH HORMONE SYNDROME
Geffner, M. E. (1996) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70345-5 · Cited by 108 · cited 1×
“phenomenon is unknown (3), but has been linked, depend-”
BackgroundSelf-citation
Cited by
Karavitaki, N., Cudlip, S., Adams, C. B. T., & Wass, J. A. H. (2006) · Endocrine Reviews · doi:10.1210/er.2006-0002 · Cited by 514
Müller, H. L. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1115 · Cited by 401
Collett-Solberg, P. F., Ambler, G., Backeljauw, P. F., Bidlingmaier, M., Biller, B. M. K., Boguszewski, M. C. S., Cheung, P. T., Choong, C. S. Y., Cohen, L. E., Cohen, P., et al. (2019) · Hormone Research in Paediatrics · doi:10.1159/000502231 · Cited by 360
van Iersel, L., Brokke, K. E., Adan, R. A. H., Bulthuis, L. C. M., van den Akker, E. L. T., & van Santen, H. M. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00017 · Cited by 146
Müller, H. L., Tauber, M., Lawson, E. A., Özyurt, J., Bison, B., Martinez-Barbera, J.-P., Puget, S., Merchant, T. E., & van Santen, H. M. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00351-z · Cited by 144
Metadata
- Authors
- Geffner, M., Lundberg, M., Koltowska-Häggström, M., Abs, R., Verhelst, J., Erfurth, E. M., Kendall-Taylor, P., Price, D. A., Jonsson, P., & Bakker, B.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2004-11-01
- Volume
- 89
- Issue
- 11
- Pages
- 5435-5440
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2065364017
- Cited by
- 95
- References
- 2
- FWCI
- 2.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Changes in Height, Weight, and Body Mass Index in Children with Craniopharyngioma after Three Years of Growth Hormone Therapy: Analysis of KIGS (Pfizer International Growth Database). https://app.cochat.ai/papers/10.1210/jc.2004-0667
- The paper
- Geffner, M., Lundberg, M., Koltowska-Häggström, M., Abs, R., Verhelst, J., Erfurth, E. M., Kendall-Taylor, P., Price, D. A., Jonsson, P., & Bakker, B. (2004). Changes in Height, Weight, and Body Mass Index in Children with Craniopharyngioma after Three Years of Growth Hormone Therapy: Analysis of KIGS (Pfizer International Growth Database). The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2004-0667
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.